Abstract Sentinel lymph node biopsy has been the standard axillary intervention for breast cancer patients with clinical negative axillary lymph nodes. Complete axillary dissection could be omitted for patients with negative sentinel lymph nodes. While, the optimal axillary intervention for patients with 1-2 positive sentinel lymph nodes remained controversial. This review introduced the latest research results of the axillary management for early stage breast cancer patients with 1-2 positive sentinel lymph nodes.
Zhang Li,Yu Xiaoli,Guo Xiaomao. Research progress of axillary management approach for 1-2 sentinel lymph node positive early stage breast cancer patients[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 292-295.
Zhang Li,Yu Xiaoli,Guo Xiaomao. Research progress of axillary management approach for 1-2 sentinel lymph node positive early stage breast cancer patients[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 292-295.
[1] Morton DL,Wen DR,Wong JH,et al. Technical details of intraoperative lymphatic mapping for early stage melanoma[J].Arch Surg,1992,127(4):392-399.DOI:10.1001/archsurg.1992.01420040034005. [2] Albertini JJ,Lyman GH,Cox C,et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer[J].JAMA,1996,276(22):1818-1822.DOI:10.1001/jama.1996.03540220042028. [3] Veronesi U,Paganelli G,Viale G,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J].N Engl J Med,2003,349(6):546-553.DOI:10.1056/NEJMoa012782. [4] Krag DN,Anderson SJ,Julian TB,et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial[J].Lancet Oncol,2010,11(10):927-933.DOI:10.1016/S1470-2045(10)70207-2. [5] Lyman GH,Giuliano AE,Somerfield MR,et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J].J Clin Oncol,2005,23(30):7703-7720.DOI:10.1200/JCO.2005.08.001. [6] Giuliano AE,Hunt KK,Ballman KV,et al. Axillary dissection 与 no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J].JAMA,2011,305(6):569-575.DOI:10.1001/jama.2011.90. [7] Galimberti V,Cole BF,Zurrida S,et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01):a phase 3 randomised controlled trial[J].Lancet Oncol,2013,14(4):297-305.DOI:10.1016/S1470-2045(13)70035-4. [8] Lyman GH,Temin S,Edge SB,et al. Sentinel lymph node biopsy for patients with early-stage breast cancer:American Society of Clinical Oncology clinical practice guideline update[J].J Clin Oncol,2014,32(13):1365-1383.DOI:10.1200/JCO.2013.54.1177. [9] Giuliano AE,McCall L,Beitsch P,et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases:the American College of Surgeons Oncology Group Z0011 randomized trial[J].Ann Surg,2010,252(3):426-432.DOI:10.1097/SLA.0b013e3181f08f32. [10] Cotlar AM,Dubose JJ,Rose DM.History of surgery for breast cancer:radical to the sublime[J].Curr Surg,2003,60(3):329-337.DOI:10.1016/S0149-7944(02)00777-8. [11] Halsted WS.I.The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June,1889,to January,1894[J].Ann Surg,1894,20(5):497-555. [12] Sávolt ,Polgár C,Musonda P,et al. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?[J].Clin Breast Cancer,2013,13(5):364-370.DOI:10.1016/j.clbc.2013.04.004. [13] Straver ME,Meijnen P,van Tienhoven G,et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer[J].J Clin Oncol,2010,28(5):731-737.DOI:10.1200/JCO.2008.21.7554. [14] van de Vijver MJ,He YD,Van′t Veer LJ,et al. A gene-expression signature as a predictor of survival in breast cancer[J].N Engl J Med,2002,347(25):1999-2009.DOI:10.1056/NEJMoa021967. [15] Buyse M,Loi S,Van′t Veer L,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J].J Natl Cancer Inst,2006,98(17):1183-1192.DOI:10.1093/jnci/djj329. [16] Paik S,Shak S,Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer[J].N Engl J Med,2004,351(27):2817-2826.DOI:10.1056/NEJMoa041588. [17] Paik S,Tang G,Shak S,et al. Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer[J].J Clin Oncol,2006,24(23):3726-3734.DOI:10.1200/JCO.2005.04.7985. [18] Kohrt HE,Olshen RA,Bermas HR,et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients[J].BMC Cancer,2008,8(1):66.DOI:10.1186/1471-2407-8-66. [19] Van Zee KJ,Manasseh DME,Bevilacqua JL,et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy[J].Ann Surg Oncol,2003,10(10):1140-1151.DOI:10.1245/ASO.2003.03.015. [20] Meretoja TJ,Leidenius MHK,Heikkil PS,et al. International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer[J].J Natl Cancer Inst,2012,104(24):1888-1896.DOI:10.1093/jnci/djs455. [21] Meretoja TJ,Audisio RA,Heikkil PS,et al. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases[J].Breast Cancer Res Treat,2013,138(3):817-827.DOI:10.1007/s10549-013-2468-3. [22] Liu M,Wang S,Pan L,et al. A new model for predicting non-sentinel lymph node status in Chinese sentinel lymph node positive breast cancer patients[J].PLoS One,2014,9(8):e104117.DOI:10.1371/journal.pone.0104117. [23] Chen JY,Chen JJ,Yang BL,et al. Predicting sentinel lymph node metastasis in a Chinese breast cancer population:assessment of an existing nomogram and a new predictive nomogram[J].Breast Cancer Res Treat,2012,135(3):839-848.DOI:10.1007/s10549-012-2219-x. [24] Voduc KD,Cheang MCU,Tyldesley S,et al. Breast cancer subtypes and the risk of local and regional relapse[J].J Clin Oncol,2010,28(10):1684-1691.DOI:10.1200/JCO.2009.24.9284. [25] Jagsi R,Chadha M,Moni J,et al. Radiation field design in the ACOSOG Z0011(Alliance) Trial[J].J Clin Oncol,2014,32(32):3600-3606.DOI:10.1200/JCO.2014.56.5838. [26] Krasin M,McCall A,King S,et al. Evaluation of a standard breast tangent technique:a dose-volume analysis of tangential irradiation using three-dimensional tools[J].Int J Radiat Oncol Biol Phys,2000,47(2):327-333.DOI:10.1016/S0360-3016(00)00449-1. [27] Aristei C,Chionne F,Marsella AR,et al. Evaluation of level I and Ⅱ axillary nodes included in the standard breast tangential fields and calculation of the administered dose:results of a prospective study[J].Int J Radiat Oncol Biol Phys,2001,51(1):69-73.DOI:10.1016/S0360-3016(01)01595-4. [28] Orecchia R,Huscher A,Leonardi MC,et al. Irradiation with standard tangential breast fields in patients treated with conservative surgery and sentinel node biopsy:using a three-dimensional tool to evaluate the first level coverage of the axillary nodes[J].Br J Radiol,2005,78(925):51-54.DOI:10.1259/bjr/29242407. [29] 张丽,王玉洁,俞晓立,等.乳腺癌保乳术后全乳逆向IMRT对腋窝I—Ⅲ站及前哨淋巴结剂量覆盖评估[J].中华放射肿瘤学杂志,2014,23(6):468-471.DOI:10.3760/cma.j.issn.1004-4221.2014.06.002. Zhang L,Wang YJ,Yu XL,et al.Dose coverage of axillary levels I-III and sentinel lymph node area by inverse-planned intensity-modulated radiotherapy for whole breast irradiation in patients with breast cancer after breast-conserving surgery[J].Chin J Radiat Oncol,2014,23(6):468-471.DOI:10.3760/cma.j.issn.1004-4221.2014.06.002. [30] Reznik J,Cicchetti MG,Degaspe B,et al. Analysis of axillary coverage during tangential radiation therapy to the breast[J].Int J Radiat Oncol Biol Phys,2005,61(1):163-168.DOI:10.1016/j.ijrobp.2004.04.065. [31] Belkacemi Y,Allab-Pan Q,Bigorie V,et al. The standard tangential fields used for breast irradiation do not allow optimal coverage and dose distribution in axillary levels Ⅰ-Ⅱ and the sentinel node area[J].Ann Oncol,2013,24(8):2023-2028.DOI:10.1093/annonc/mdt151. [32] Donker M,van Tienhoven G,Straver ME,et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomised,multicentre,open-label,phase 3 non-inferiority trial[J].Lancet Oncol,2014,15(12):1303-1310.DOI:10.1016/S1470-2045(14)70460-7. [33] Straver ME,Rutgers EJT,Russell NS,et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer[J].Eur J Cancer,2009,45(13):2284-2292.DOI:10.1016/j.ejca.2009.04.029. [34] Rouzier R,Extra JM,Klijanienko J,et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes[J].J Clin Oncol,2002,20(5):1304-1310.DOI:10.1200/JCO.20.5.1304. [35] Alvarado R,Yi M,Le-Petross H,et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J].Ann Surg Oncol,2012,19(10):3177-3184.DOI:10.1245/s10434-012-2484-2. [36] Mamounas EP,Anderson SJ,Dignam JJ,et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy:results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27[J].J Clin Oncol,2012,30(32):3960-3966.DOI:10.1200/JCO.2011.40.8369. [37] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,365(9472):1687-1717.DOI:10.1016/S0140-6736(05)66544-0. [38] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG),Davies C,Godwin J,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.DOI:10.1016/S0140-6736(11)60993-8.
2016, Vol. 25 
